PTH and osteoporosis: These findings indicate that senescent osteoblast‐lineage‐enriched cells contribute to bone fragility and post‐treatment bone loss in aged individuals, suggesting that targeting senescence may enhance the efficacy and sustainability of PTH therapy for osteoporosis.